Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients

This study has been terminated.
(Enrollment target not reached)
Information provided by (Responsible Party):
Dompé Farmaceutici S.p.A
ClinicalTrials.gov Identifier:
First received: April 18, 2013
Last updated: October 12, 2015
Last verified: October 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)